Advancing Early-Stage Bispecific Discovery Programs Towards Clinical Success, With GS Discovery® and bYlok® Technology

Watch this webinar with Dr. Jin Lu to learn how Lonza’s novel expression tools can advance your bispecific antibody discovery programs. Our GS Discovery® transient expression platform can boost transient titers by ~30-fold to enable rapid early material supply and streamline the transition from discovery to stable production. What’s more, our bYlok® technology increases bispecific yields and simplifies downstream processing by driving correct heavy-light chain pairing to >95%.